Speaker(s): 

Shannon Brown, PharmD, Resident - has nothing to disclose 

Rosine Richa, PharmD, BCPS, Resident - has nothing to disclose 

Abigail Perriello, PharmD, Resident- has nothing to disclose 

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the interconnected pathophysiology of cardiovascular disease, chronic kidney disease and metabolic syndrome. 
• Discuss the role of SGLT2 inhibitors in managing cardiovascular, renal, and metabolic conditions. 
• Identify individuals who would benefit from early initiation of SGLT2 inhibitor therapy. 
• Apply current clinical practice guidelines into decision-making processes to optimize the use of SGLT2 inhibitors in managing type II diabetes mellitus, heart failure, and chronic kidney disease.  

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None